A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin, and enoxaparin in plasma

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 5, 2016, Pages 1043-1053

  Letertre, L R ^a   Gudmundsdottir, B R ^a   Francis, C W ^b   Gosselin, R C ^c   Skeppholm, M ^d   Malmstrom, R E ^e   Moll, S ^f   Hawes, E ^f,g   Francart, S ^g   Onundarson, P T ^a,h  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DANDERYD HOSPITAL   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h UNIVERSITY OF ICELAND   (Iceland)

Author keywords

Apixaban; Assay; Dabigatran; Heparin; Rivaroxaban

Indexed keywords

APIXABAN; BLOOD CLOTTING FACTOR 10; DABIGATRAN; ENOXAPARIN; HEPARIN; PROTHROMBIN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; FONDAPARINUX; POLYSACCHARIDE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; THROMBOPLASTIN;

ANALYTIC METHOD; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; BLOOD LEVEL; BLOOD SAMPLING; DILUTED FIIX PROTHROMBIN TIME; DILUTED PROTHROMBIN TIME; DILUTED THROMBIN TIME; DRUG DETERMINATION; DRUG USE; HUMAN; MEASUREMENT; PRIORITY JOURNAL; SINGLE TEST; BLOOD; BLOOD CLOTTING TEST; BLOOD DONOR; CALIBRATION; CHEMISTRY; FEMALE; INTERNATIONAL NORMALIZED RATIO; MALE; PROCEDURES; PROTHROMBIN TIME; REPRODUCIBILITY;

ANTICOAGULANTS; BLOOD COAGULATION TESTS; BLOOD DONORS; CALIBRATION; DABIGATRAN; ENOXAPARIN; FACTOR X; FEMALE; HEPARIN; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; POLYSACCHARIDES; PROTHROMBIN; PROTHROMBIN TIME; PYRAZOLES; PYRIDONES; REPRODUCIBILITY OF RESULTS; RIVAROXABAN; THROMBOPLASTIN; WARFARIN;

EID: 84963657183     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13300     Document Type: Article

References (24)

1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
2. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.
3. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-510.
4. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-104.
5. Francart SJ, Hawes EM, Deal AM, Adcock DM, Gosselin R, Jeanneret C, Friedman KD, Moll S. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb Haemost 2014; 111: 1133-40.
6. Hawes EM, Deal AM, Funk-Adcock D, Gosselin R, Jeanneret C, Cook AM, Taylor JM, Whinna HC, Winkler AM, Moll S. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 2013; 11: 1493-502.
7. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogne JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107: 985-97.
8. Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Lindahl TL. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011; 9: 133-9.
9. Skeppholm M, Hjemdahl P, Antovic JP, Muhrbeck J, Eintrei J, Ronquist-Nii Y, Pohanka A, Beck O, Malmstrom RE. On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation. Thromb Res 2014; 134: 783-9.
10. Samama MM, Contant G, Spiro TE, Perzborn E, Le Flem L, Guinet C, Gourmelin Y, Rohde G, Martinoli JL. Laboratory assessment of rivaroxaban: a review. Thromb J 2013; 11: 11.
11. Gerbutavicius R, Iqbal O, Messmore HL, Wehrmacher WH, Hoppensteadt DA, Gerbutaviciene R, Griniute R, Fareed J. Differential effects of DX-9065a, argatroban, and synthetic pentasaccharide on tissue thromboplastin inhibition test and dilute Russell's viper venom test. Clin Appl Thromb Hemost 2003; 9: 317-23.
12. Gudmundsdottir BR, Francis CW, Bjornsdottir AM, Nellbring M, Onundarson PT. Critical role of factors II and X during coumarin anticoagulation and their combined measurement with a new Fiix-prothrombin time. Thromb Res 2012; 130: 674-81.
13. Onundarson PT, Francis CW, Indridason OS, Arnar DO, Bjornsson ES, Magnusson MK, Juliusson SJ, Jensdottir HM, Vidarsson B, Gunnarsson PS, Lund SH, Gudmundsdottir BR. Fiix-prothrombin time versus standard prothrombin time for monitoring of warfarin anticoagulation: a single centre, double-blind, randomised, non-inferiority trial. Lancet Haemato 2015; 2: e231-e40.
14. Lippi G, Favaloro EJ. Laboratory monitoring of warfarin in the era of direct oral anticoagulants (editorial comment). Lancet Haemato 2015; 2: e223-e4.
15. Douxfils J, Chatelain B, Hjemdahl P, Devalet B, Sennesael AL, Wallemacq P, Ronquist-Nii Y, Pohanka A, Dogne JM, Mullier F. Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study. Thromb Res 2015; 135: 852-60.
16. Douxfils J, Dogne JM, Mullier F, Chatelain B, Ronquist-Nii Y, Malmstrom RE, Hjemdahl P. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 2013; 110: 543-9.
17. Douxfils J, Tamigniau A, Chatelain B, Chatelain C, Wallemacq P, Dogne JM, Mullier F. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 2013; 110: 723-31.
18. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L, Investigators R-L. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014; 63: 321-8.
19. European Medicines Agency. Pradaxa - Summary of Product Characteristics. Pradaxa EMA, ed., 2014.
20. Cohen D. Dabigatran: how the drug company withheld important analyses. BMJ 2014; 349: g4670.
21. Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, Rosencher N, Schved JF, de Maistre E, Samama MM, Mismetti P, Sie P; Working Group on Perioperative Haemostasis. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. Arch Cardiovasc Dis 2013; 106: 382-93.
22. Brufatto N, Ward A, Nesheim ME. Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex. J Thromb Haemost 2003; 1: 1258-63.
23. Yau JW, Stafford AR, Liao P, Fredenburgh JC, Roberts R, Weitz JI. Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. Blood 2011; 118: 6667-74.
24. Gruber A, Tucker EI. Size matters. Blood 2011; 118: 6481-2.